



Abacus Health Products Hires Vice President of Marketing and Vice President of Sales

(Woonsocket, RI – April 17, 2019) Abacus Health Products, Inc. (CSE: ABCS) (“Abacus” or the “Company”) today announced the hiring of two new members to its senior management team.

James Barkat has been named Vice President of Marketing for Abacus. Prior to joining the Company, Mr. Barkat spent over ten years at Sanofi Consumer Health, where he most recently served as U.S. Marketing Head – Digestive Health, a \$300 million portfolio that includes brands such as Dulcolax, Zantac, and Roloids. Mr. Barkat has over 20 years experience in the over-the-counter pharmaceutical industry, including new OTC classifications and product launches, and has marketed in joint collaboration with 10 major U.S. retailers.

The Company also announced that Mark Bolling has been named Vice President of Sales for Abacus. Mr. Bolling joins the Company with more than 25 years of business development, sales, and marketing experience spanning diverse industries and product lines. Most recently, he served as the Vice President of Business Development – Commercial Sales for PuraCap Pharmaceutical, a manufacturer and distributor of pharmaceutical and healthcare products for the United States and international markets. There, Mr. Bolling rapidly and successfully turned around the sales and marketing functions of the business, including the rebuilding of the international sales team.

“James and Mark join the Abacus team with a wealth of experience and proven track records in delivering marketing and sales excellence in the healthcare and pharmaceutical space,” said Perry Antelman, CEO of Abacus. “Individuals of their quality on our senior management team will prove to be critical in the success of the Company as we continue to expand the offering and availability of both CBDMEDIC™ and CBD CLINIC™ product lines in the American market.”

###

About Abacus Health Products

Abacus is a company engaged in the development and commercialization of over-the-counter (OTC) registered topical medications with active pharmaceutical ingredients and which contain organic and natural ingredients, including a cannabinoid-rich hemp extract containing CBD from Cannabis sativa L plant. Abacus’ products are aimed at the rapidly growing markets for topical pain relief and therapeutic skincare and are based on proprietary patent-pending technologies developed by Abacus. Abacus’ formulations combine advanced science with organic and natural ingredients to provide safe relief. Abacus currently offers two lines of products: (i) CBD CLINIC™, marketed to the professional practitioner market, and (ii) CBDMEDIC™, marketed to the consumer market. Abacus’ products are offered across

the United States and are produced by a contract manufacturer in a cGMP compliant and audited manufacturing facility.

For further information: please contact **Hank Hague, CFO**, of the Company, at 416-848-1457 or investorrelations@abacushp.com